0001780490-24-000001.txt : 20240513 0001780490-24-000001.hdr.sgml : 20240513 20240513121153 ACCESSION NUMBER: 0001780490-24-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 EFFECTIVENESS DATE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ajax Therapeutics, Inc. CENTRAL INDEX KEY: 0001780490 ORGANIZATION NAME: IRS NUMBER: 834655405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-513064 FILM NUMBER: 24937781 BUSINESS ADDRESS: STREET 1: 275 MADISON AVE, 39TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 646-361-0100 MAIL ADDRESS: STREET 1: 275 MADISON AVE, 39TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 D 1 primary_doc.xml X0708 D LIVE 0001780490 Ajax Therapeutics, Inc. 275 MADISON AVE, 39TH FLOOR NEW YORK NY NEW YORK 10016 917-410-7250 DELAWARE None None Corporation true 2019 Martin Vogelbaum c/o Ajax Therapeutics, Inc. 275 Madison Ave, 39th Floor New York NY NEW YORK 10016 Executive Officer Director Scott Platshon c/o Ajax Therapeutics, Inc. 275 Madison Ave, 39th Floor New York NY NEW YORK 10016 Director Ramy Farid c/o Ajax Therapeutics, Inc. 275 Madison Ave, 39th Floor New York NY NEW YORK 10016 Director Ross Levine c/o Ajax Therapeutics, Inc. 275 Madison Ave, 39th Floor New York NY NEW YORK 10016 Director Biotechnology Decline to Disclose 06b false 2024-04-26 false true false 0 95000000 95000000 0 The total amount includes committed amounts to be paid to the Issuer in the future. false 21 0 0 0 false Ajax Therapeutics, Inc. /s/ Martin Vogelbaum Martin Vogelbaum Chief Executive Officer 2024-05-13